{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:47:15Z","timestamp":1754110035267},"reference-count":75,"publisher":"Bentham Science Publishers Ltd.","issue":"17","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Infection with SARS-CoV-2 leads to COVID-19 which can manifest in various ways from asymptomatic or mild disease to acute respiratory distress syndrome. The occur-rence of dysregulated inflammatory responses in the form of a cytokine storm has been reported in patients with severe COVID-19. Infection can also lead to dysfunctional hemostasis reflected in el-evated circulating D-dimer and fibrin degradation products. Components of hemostasis and the im-mune system during infection can result in a procoagulation and\/or proinflammatory state. The in-terplay between coagulation and inflammation has been elucidated in a number of diseases.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>In this article, we discuss the occurrence of cytokine storms and dysfunctional hemosta-sis induced in COVID-19.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>This review was written using literature from the past two to three years investigating co-agulation and inflammation in COVID-19. Additional literature, both clinical and basic research, related to pathogen infection and host responses were also considered in this review.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results\/Conclusions:<\/jats:title>\n<jats:p>Infection with SARS-CoV-2 can lead to dysregulated inflammatory respons-es that may be detrimental to the host. The increased expression of various inflammatory factors can ultimately create an environment that promotes thrombosis.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389450124666221025102929","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T04:30:15Z","timestamp":1666758615000},"page":"1603-1610","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["COVID-19 Induces Cytokine Storm and Dysfunctional Hemostasis"],"prefix":"10.2174","volume":"23","author":[{"given":"Victoria A.","family":"Ploplis","sequence":"first","affiliation":[{"name":"W.M. Keck Center for Transgene Research, University of Notre Dame, Notre Dame, IN 46556, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jermilia","family":"Charles","sequence":"additional","affiliation":[{"name":"W.M. Keck Center for Transgene Research, University of Notre Dame, Notre Dame, IN 46556, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","author":"Molnar C.","year":"2015","unstructured":"Molnar C.; Gair J.; Concepts of biology-1st Canadian edition. In: Concepts Biol. BC campus 2015"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.molimm.2004.06.016","volume":"42","author":"Alfano M.","year":"2005","unstructured":"Alfano M.; Poli G.; Role of cytokines and chemokines in the regulation of innate immunity and HIV infection. Mol Immunol 2005,42(2),161-182","journal-title":"Mol Immunol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.chom.2018.12.006","volume":"25","author":"Netea M.G.","year":"2019","unstructured":"Netea M.G.; Schlitzer A.; Placek K.; Joosten L.A.B.; Schultze J.L.; Innate and adaptive immune memory: an evolutionary continuum in the host\u2019s response to pathogens. Cell Host Microbe 2019,25(1),13-26","journal-title":"Cell Host Microbe"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12328-021-01555-8","volume":"15","author":"Kumar S.","year":"2022","unstructured":"Kumar S.; Singh P.; Kumar A.; Targeted therapy of irritable bowel syndrome with anti-inflammatory cytokines. Clin J Gastroenterol 2022,15(1),1-10","journal-title":"Clin J Gastroenterol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.3389\/fonc.2019.01529","volume":"9","author":"Thakar M.S.","year":"2020","unstructured":"Thakar M.S.; Kearl T.J.; Malarkannan S.; Controlling cytokine release syndrome to harness the full potential of CAR-based cellular therapy. Front Oncol 2020,9,1529","journal-title":"Front Oncol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/08830185.2021.1884248","volume":"41","author":"Que Y.","year":"2022","unstructured":"Que Y.; Hu C.; Wan K.; Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality. Int Rev Immunol 2022,41(2),217-230","journal-title":"Int Rev Immunol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.3389\/fimmu.2020.01446","volume":"11","author":"Ragab D.","year":"2020","unstructured":"Ragab D.; Salah E.H.; Taeimah M.; Khattab R.; Salem R.; The COVID-19 Cytokine Storm; What We Know So Far. Front Immunol 2020,11,1446","journal-title":"Front Immunol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/cmi.2015.74","volume":"13","author":"Liu Q.","year":"2016","unstructured":"Liu Q.; Zhou Y.; Yang Z.; The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol 2016,13(1),3-10","journal-title":"Cell Mol Immunol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"Fajgenbaum D.C.","year":"2020","unstructured":"Fajgenbaum D.C.; June C.H.; Cytokine storm. N Engl J Med 2020,383(23),2255-2273","journal-title":"N Engl J Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"101(Pt B): 108254","DOI":"10.1016\/j.intimp.2021.108254","author":"Zhou B","year":"2021","unstructured":"Zhou B; Li S; Ye J; Immunopathological events surrounding IL-6 and IFN-&#x3B1;: A bridge for anti-lupus erythematosus drugs used to treat COVID-19. Int Immunopharmacol 2021,101(Pt B): 108254"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"108652","DOI":"10.1016\/j.clim.2020.108652","volume":"223","author":"Ryabkova V.A.","year":"2021","unstructured":"Ryabkova V.A.; Churilov L.P.; Shoenfeld Y.; Influenza infection, SARS, MERS and COVID-19: Cytokine storm - The common denominator and the lessons to be learned. Clin Immunol 2021,223,108652","journal-title":"Clin Immunol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1038\/s41591-021-01500-9","volume":"27","author":"Cron R.Q.","year":"2021","unstructured":"Cron R.Q.; Caricchio R.; Chatham W.W.; Calming the cytokine storm in COVID-19. Nat Med 2021,27(10),1674-1675","journal-title":"Nat Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.immuni.2020.06.017","volume":"53","author":"Mangalmurti N.","year":"2020","unstructured":"Mangalmurti N.; Hunter C.A.; Cytokine Storms: Understanding COVID-19. Immunity 2020,53(1),19-25","journal-title":"Immunity"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jinf.2020.03.037","volume":"80","author":"Ye Q.","year":"2020","unstructured":"Ye Q.; Wang B.; Mao J.; The pathogenesis and treatment of the \u2018Cytokine Storm\u2019 in COVID-19. J Infect 2020,80(6),607-613","journal-title":"J Infect"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00011-020-01372-8","volume":"69","author":"Meftahi G.H.","year":"2020","unstructured":"Meftahi G.H.; Jangravi Z.; Sahraei H.; Bahari Z.; The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of &#x201C;inflame-aging&#x201D;. Inflamm Res 2020,69(9),825-839","journal-title":"Inflamm Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41392-021-00679-0","volume":"6","author":"Yang L.","year":"2021","unstructured":"Yang L.; Xie X.; Tu Z.; Fu J.; Xu D.; Zhou Y.; The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct Target Ther 2021,6(1),255","journal-title":"Signal Transduct Target Ther"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"101(Pt A): 108172","DOI":"10.1016\/j.intimp.2021.108172","author":"Aslani M","year":"2021","unstructured":"Aslani M; Mortazavi-Jahromi SS; Mirshafiey A; Cytokine storm in the pathophysiology of COVID-19: Possible functional disturbances of miRNAs. Int Immunopharmacol 2021,101(Pt A): 108172"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1365-2141.2005.05753.x","volume":"131","author":"Esmon C.T.","year":"2005","unstructured":"Esmon C.T.; The interactions between inflammation and coagulation. Br J Haematol 2005,131(4),417-430","journal-title":"Br J Haematol"},{"key":"ref=19","first-page":"S26","volume":"38","author":"Levi M.","year":"2010","unstructured":"Levi M.; van der Poll T.; Inflammation and coagulation. In: Crit Care Med 2010,38(S2),S26-S34","journal-title":"In: Crit Care Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"749569","DOI":"10.3389\/fmed.2021.749569","volume":"8","author":"Markovic S.S.","year":"2021","unstructured":"Markovic S.S.; Jovanovic M.; Gajovic N.; IL 33 Correlates With COVID-19 Severity, Radiographic and Clinical Finding. Front Med 2021,8,749569","journal-title":"Front Med"},{"key":"ref=21","first-page":"2020.04.22.20072124","author":"Williams F.M.K.","year":"2020","unstructured":"Williams F.M.K.; Self-reported symptoms of covid-19 including symptoms most predictive of SARS-CoV-2 infection, are heritable medRxiv 2020,2020.04.22.20072124","journal-title":"medRxiv"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.3389\/fimmu.2020.02132","volume":"11","author":"Castelli V.","year":"2020","unstructured":"Castelli V.; Cimini A.; Ferri C.; Cytokine Storm in COVID-19: &#x201C;When You Come Out of the Storm, You Won\u2019t Be the Same Person Who Walked in&#x201D;. Front Immunol 2020,11,2132","journal-title":"Front Immunol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.12182\/20210160206","volume":"52","author":"Tang Y.Y.","year":"2021","unstructured":"Tang Y.Y.; Lou G.X.; He W.F.; Analysis of the development mechanism of cytokine storm in severe burn patients complicated with infection. Sichuan Da Xue Xue Bao Yi Xue Ban 2021,52(1),16-21","journal-title":"Sichuan Da Xue Xue Bao Yi Xue Ban"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/annrheumdis-2020-218479","volume":"79","author":"Ramiro S.","year":"2020","unstructured":"Ramiro S.; Mostard R.L.M.; Magro-Checa C.; Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study. Ann Rheum Dis 2020,79(9),1143-1151","journal-title":"Ann Rheum Dis"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1080\/14787210.2021.1915129","volume":"19","author":"Savla S.R.","year":"2021","unstructured":"Savla S.R.; Prabhavalkar K.S.; Bhatt L.K.; Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and man-agement. Expert Rev Anti Infect Ther 2021,19(11),1397-1413","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.3389\/fimmu.2019.01265","volume":"10","author":"Lotfi N.","year":"2019","unstructured":"Lotfi N.; Thome R.; Rezaei N.; Roles of GM-CSF in the pathogenesis of autoimmune diseases: An update. Front Immunol 2019,10,1265","journal-title":"Front Immunol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1021\/acschemneuro.0c00447","volume":"11","author":"Cazzolla A.P.","year":"2020","unstructured":"Cazzolla A.P.; Lovero R.; Lo Muzio L.; Taste and smell disorders in COVID-19 Patients: Role of interleukin-6. ACS Chem Neurosci 2020,11(17),2774-2781","journal-title":"ACS Chem Neurosci"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"104370","DOI":"10.1016\/j.jcv.2020.104370","volume":"127","author":"Liu F.","year":"2020","unstructured":"Liu F.; Li L.; Xu M.; Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol 2020,127,104370","journal-title":"J Clin Virol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.1021\/acs.jproteome.0c00365","volume":"19","author":"D\u2019Alessandro A.","year":"2020","unstructured":"D\u2019Alessandro A.; Thomas T.; Dzieciatkowska M.; Serum proteomics in COVID-19 patients: Altered coagulation and complement status as a function of IL-6 Level. J Proteome Res 2020,19(11),4417-4427","journal-title":"J Proteome Res"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"eabg9873","DOI":"10.1126\/sciimmunol.abg9873","volume":"6","author":"Thwaites R.S.","year":"2021","unstructured":"Thwaites R.S.; Sanchez Sevilla Uruchurtu A.; Siggins M.K.; Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. Sci Immunol 2021,6(57),eabg9873","journal-title":"Sci Immunol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1186\/s12967-020-02646-9","volume":"18","author":"Blot M.","year":"2020","unstructured":"Blot M.; Bour J.B.; Quenot J.P.; The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome. J Transl Med 2020,18(1),457","journal-title":"J Transl Med"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"e0241875","DOI":"10.1101\/2020.10.11.20210922","volume":"16","author":"Dixon B.E.","year":"2021","unstructured":"Dixon B.E.; Wools-Kaloustian K.K.; Fadel W.F.; Symptoms and symptom clusters associated with SARS-CoV-2 infection in communi-ty-based populations: Results from a statewide epidemiological study. PLoS One 2021,16(3),e0241875","journal-title":"PLoS One"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"698169","DOI":"10.3389\/fmicb.2021.698169","volume":"12","author":"Proal A.D.","year":"2021","unstructured":"Proal A.D.; VanElzakker M.B.; Long COVID or Post-acute Sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms. Front Microbiol 2021,12,698169","journal-title":"Front Microbiol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"864","DOI":"10.4065\/82.7.864","volume":"82","author":"Kamal A.H.","year":"2007","unstructured":"Kamal A.H.; Tefferi A.; Pruthi R.K.; How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc 2007,82(7),864-873","journal-title":"Mayo Clin Proc"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/jcla.10072","volume":"17","author":"Moresco R.N.","year":"2003","unstructured":"Moresco R.N.; Vargas L.C.R.; Voegeli C.F.; Santos R.C.V.; D-dimer and its relationship to fibrinogen\/Fibrin Degradation Products (FDPs) in disorders associated with activation of coagulation or fibrinolytic systems. J Clin Lab Anal 2003,17(3),77-79","journal-title":"J Clin Lab Anal"},{"key":"ref=36","first-page":"607","author":"Zimring J.C.","year":"2009","unstructured":"Zimring J.C.;  Chapter 113 Prothrombin Time and Activated Partial Thromboplastin Time 2009,607-610","journal-title":"Chapter 113 Prothrombin Time and Activated Partial Thromboplastin Time"},{"key":"ref=37","author":"Neville K.A.","unstructured":"Neville K.A.; Wicklund B.M.; Woods G.M.; Chapter 5 - COAGULOPATHIES AND SICKLE CELL DISEASE. 5th ed. Ostlie. Philadelphia: W.B. Saunders 2010; pp. 61-73."},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/jth.14768","volume":"18","author":"Tang N.","year":"2020","unstructured":"Tang N.; Li D.; Wang X.; Sun Z.; Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020,18(4),844-847","journal-title":"J Thromb Haemost"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/jth.14817","volume":"18","author":"Tang N.","year":"2020","unstructured":"Tang N.; Bai H.; Chen X.; Gong J.; Li D.; Sun Z.; Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020,18(5),1094-1099","journal-title":"J Thromb Haemost"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00277-020-04305-x","volume":"100","author":"Luo H.","year":"2021","unstructured":"Luo H.; You C.; Lu S.; Fu Y.; Characteristics of coagulation alteration in patients with COVID-19. Ann Hematol 2021,100(1),45-52","journal-title":"Ann Hematol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1161\/CIRCULATIONAHA.120.046702","volume":"142","author":"Zhang L.","year":"2020","unstructured":"Zhang L.; Feng X.; Zhang D.; Deep vein thrombosis in hospitalized patients with COVID-19 in Wuhan, China. Circulation 2020,142(2),114-128","journal-title":"Circulation"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"2100116","DOI":"10.1183\/13993003.00116-2021","volume":"58","author":"Jevnikar M.","year":"2021","unstructured":"Jevnikar M.; Sanchez O.; Chocron R.; Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admis-sion. Eur Respir J 2021,58(1),2100116","journal-title":"Eur Respir J"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fcimb.2014.00128","volume":"4","author":"Loof T.G.","year":"2014","unstructured":"Loof T.G.; Deicke C.; Medina E.; The role of coagulation\/fibrinolysis during Streptococcus pyogenes infection. Front Cell Infect Microbiol 2014,4,128","journal-title":"Front Cell Infect Microbiol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.thromres.2004.06.028","volume":"114","author":"Esmon C.T.","year":"2004","unstructured":"Esmon C.T.; The impact of the inflammatory response on coagulation. Thromb Res 2004,114(5-6),321-327","journal-title":"Thromb Res"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3748\/wjg.v17.i5.594","volume":"17","author":"Scaldaferri F.","year":"2011","unstructured":"Scaldaferri F.; Lancellotti S.; Pizzoferrato M.; De Cristofaro R.; Haemostatic system in inflammatory bowel diseases: New players in gut inflammation. World J Gastroenterol 2011,17(5),594-608","journal-title":"World J Gastroenterol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1055\/s-0040-1708551","volume":"120","author":"Wojta J.","year":"2020","unstructured":"Wojta J.; Macrophages and thrombin\u2014another link between inflammation and coagulation. Thromb Haemost 2020,120(4),537","journal-title":"Thromb Haemost"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1182\/blood.2020007008","volume":"136","author":"Middleton E.A.","year":"2020","unstructured":"Middleton E.A.; He X.Y.; Denorme F.; Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood 2020,136(10),1169-1179","journal-title":"Blood"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"76(4): 412 LP-20","DOI":"10.1136\/thoraxjnl-2020-21624","author":"Loo J","year":"2021","unstructured":"Loo J; Spittle D A; Newnham M.; COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. Thorax 2021,76(4): 412 LP-20"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"e20200652","DOI":"10.1084\/jem.20200652","volume":"217","author":"Barnes B.J.","year":"2020","unstructured":"Barnes B.J.; Adrover J.M.; Baxter-Stoltzfus A.; Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med 2020,217(6),e20200652","journal-title":"J Exp Med"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3389\/fimmu.2016.00271","volume":"7","author":"Carestia A.","year":"2016","unstructured":"Carestia A.; Kaufman T.; Schattner M.; Platelets: New bricks in the building of neutrophil extracellular traps. Front Immunol 2016,7,271","journal-title":"Front Immunol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/ibd.20896","volume":"15","author":"Yoshida H.","year":"2009","unstructured":"Yoshida H.; Granger N.D.; Inflammatory bowel disease. Inflamm Bowel Dis 2009,15(8),1245-1255","journal-title":"Inflamm Bowel Dis"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.2174\/138161208784980581","volume":"14","author":"Wang L.","year":"2008","unstructured":"Wang L.; Bastarache J.; Ware L.; The coagulation cascade in sepsis. Curr Pharm Des 2008,14(19),1860-1869","journal-title":"Curr Pharm Des"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1161\/ATVBAHA.117.309846","volume":"38","author":"Grover S.P.","year":"2018","unstructured":"Grover S.P.; Mackman N.; Tissue factor. Arterioscler Thromb Vasc Biol 2018,38(4),709-725","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"100761","DOI":"10.1016\/j.blre.2020.100761","volume":"47","author":"Hadid T.","year":"2021","unstructured":"Hadid T.; Kafri Z.; Al-Katib A.; Coagulation and anticoagulation in COVID-19. Blood Rev 2021,47,100761","journal-title":"Blood Rev"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1111\/jth.15451","volume":"19","author":"Subrahmanian S.","year":"2021","unstructured":"Subrahmanian S.; Borczuk A.; Salvatore S.; Tissue factor upregulation is associated with SARS\u2010CoV\u20102 in the lungs of COVID\u201019 patients. J Thromb Haemost 2021,19(9),2268-2274","journal-title":"J Thromb Haemost"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1477-9560-11-7","volume":"11","author":"Prechel M.M.","year":"2013","unstructured":"Prechel M.M.; Walenga J.M.; Emphasis on the Role of PF4 in the incidence, pathophysiology and treatment of heparin induced thrombocy-topenia. Thromb J 2013,11(1),7","journal-title":"Thromb J"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jhep.2021.04.050","volume":"75","author":"McConnell M.J.","year":"2021","unstructured":"McConnell M.J.; Kawaguchi N.; Kondo R.; Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy. J Hepatol 2021,75(3),647-658","journal-title":"J Hepatol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s10020-021-00313-3","volume":"27","author":"Li J.","year":"2021","unstructured":"Li J.; Wang P.; Tracey K.J.; Wang H.; Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines. Mol Med 2021,27(1),49","journal-title":"Mol Med"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/v11010034","volume":"11","author":"Patro A.R.K.","year":"2019","unstructured":"Patro A.R.K.; Mohanty S.; Prusty B.K.; Cytokine signature associated with disease severity in Dengue. Viruses 2019,11(1),34","journal-title":"Viruses"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1089\/vim.2019.0032","volume":"32","author":"Gu Y.","year":"2019","unstructured":"Gu Y.; Hsu A.C.Y.; Pang Z.; Role of the innate cytokine storm induced by the influenza a virus. Viral Immunol 2019,32(6),244-251","journal-title":"Viral Immunol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cyto.2005.07.007","volume":"32","author":"Theron M.","year":"2005","unstructured":"Theron M.; Huang K.; Chen Y.; Liu C.; Lei H.; A probable role for IFN-&#x3B3; in the development of a lung immunopathology in SARS. Cytokine 2005,32(1),30-38","journal-title":"Cytokine"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"e00845","DOI":"10.1128\/mBio.00845-17","volume":"8","author":"Younan P.","year":"2017","unstructured":"Younan P.; Iampietro M.; Nishida A.; Ebola virus binding to Tim-1 on T lymphocytes induces a cytokine storm. MBio 2017,8(5),e00845-e17","journal-title":"MBio"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"589474","DOI":"10.3389\/fimmu.2020.589474","volume":"11","author":"Spihlman A.P.","year":"2020","unstructured":"Spihlman A.P.; Gadi N.; Wu S.C.; Moulton V.R.; COVID-19 and Systemic Lupus Erythematosus: Focus on Immune Response and Therapeu-tics. Front Immunol 2020,11,589474","journal-title":"Front Immunol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41584-021-00709-9","volume":"17","author":"Sharma C.","year":"2021","unstructured":"Sharma C.; Ganigara M.; Galeotti C.; Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison. Nat Rev Rheumatol 2021,17(12),731-748","journal-title":"Nat Rev Rheumatol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","volume":"146","author":"Freyer C.W.","year":"2020","unstructured":"Freyer C.W.; Porter D.L.; Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol 2020,146(5),940-948","journal-title":"J Allergy Clin Immunol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jiph.2021.10.024","volume":"15","author":"Sarhan R.M.","year":"2022","unstructured":"Sarhan R.M.; Harb H.S.; Abou Warda A.E.; Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients. J Infect Public Health 2022,15(1),116-122","journal-title":"J Infect Public Health"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"246","DOI":"10.22203\/eCM.v038a17","volume":"38","author":"Black R.","year":"2019","unstructured":"Black R.; Grodzinsky A.J.; Dexamethasone: chondroprotective corticosteroid or catabolic killer? Eur Cell Mater 2019,38,246-263","journal-title":"Eur Cell Mater"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"8816","DOI":"10.1038\/s41598-021-88086-x","volume":"11","author":"Rashad A.","year":"2021","unstructured":"Rashad A.; Mousa S.; Nafady-Hego H.; Nafady A.; Elgendy H.; Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab. Sci Rep 2021,11(1),8816","journal-title":"Sci Rep"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"Kalil A.C.","year":"2021","unstructured":"Kalil A.C.; Patterson T.F.; Mehta A.K.; Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med 2021,384(9),795-807","journal-title":"N Engl J Med"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1056\/NEJMoa2101643","volume":"385","author":"Guimar&#xE3;es P.O.","year":"2021","unstructured":"Guimar&#xE3;es P.O.; Quirk D.; Furtado R.H.; Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med 2021,385(5),406-415","journal-title":"N Engl J Med"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S2213-2600(21)00099-0","volume":"9","author":"Lescure F.X.","year":"2021","unstructured":"Lescure F.X.; Honda H.; Fowler R.A.; Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, dou-ble-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 2021,9(5),522-532","journal-title":"Lancet Respir Med"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.cbpa.2009.08.017","volume":"13","author":"Laremore T.N.","year":"2009","unstructured":"Laremore T.N.; Zhang F.; Dordick J.S.; Liu J.; Linhardt R.J.; Recent progress and applications in glycosaminoglycan and heparin research. Curr Opin Chem Biol 2009,13(5-6),633-640","journal-title":"Curr Opin Chem Biol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/NEJMoa2103417","volume":"385","author":"Goligher E.C.","year":"2021","unstructured":"Goligher E.C.; Bradbury C.A.; McVerry B.J.; Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med 2021,385(9),777-789","journal-title":"N Engl J Med"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa2116846","volume":"386","author":"Gottlieb R.L.","year":"2022","unstructured":"Gottlieb R.L.; Vaca C.E.; Paredes R.; Early remdesivir to prevent progression to severe covid-19 in outpatients. N Engl J Med 2022,386(4),305-315","journal-title":"N Engl J Med"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1021\/acs.jproteome.0c00392","volume":"19","author":"Chien M.","year":"2020","unstructured":"Chien M.; Anderson T.K.; Jockusch S.; Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase, a key drug target for COVID-19. J Proteome Res 2020,19(11),4690-4697","journal-title":"J Proteome Res"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450124666221025102929","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/210348\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450124666221025102929","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T06:46:54Z","timestamp":1672037214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/210348\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":75,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450124666221025102929","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-06-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}